News

Texas biotech company CellRight Technologies sells to U.K. firm for $30M

By Jesse Pound, Staff Writer, San Antonio Express-News Photo Credit: A CellRight Technologies product ...

Winner of BioMed SA's Top Award Is Described as a 'Serial Innovator'

By Jim ForsythWOAI News Radio 1200 A man who has been dubbed a 'serial innovator,' has been named as ...

Events

BioMed SA Award For Innovation Dinner

What: Annual Award Dinner celebrating innovation in healthcare and bioscience Who: This year's honoree ...

Industry Publications

The Mission

The Mission is published by the University of Texas Health Science Center.

UTSA Discovery

UTSA Discovery is published annually for the Office of the Vice President for Research by the Office ...

News
San Antonio biotech company closer to commercializing its first device
January 13, 2017

EO2 Concepts has taken another big step toward commercializing its TransCu O2 technology. COURTESY EO2 CONCEPTS

By W. Scott Bailey, San Antonio Business Journal

EO2 Concepts, a San Antonio-based company focused on advanced wound care, has reached a key milestone en route to commercializing its initial product called the TransCu O2 System - completing a double-blind study of patients with chronic wounds treated using the technology.

The study demonstrated positive results for patients who received continuous diffusion oxygen therapy using the system, EO2 officials said. Patients and physicians involved in the study were not told which patients were wearing EO2 Concepts' device and which were being treated with a placebo.

The TransCu O2, which has received clearance from the U.S. Food and Drug Administration, is an electrochemical tissue oxygenation and wound monitoring system that provides a continuous flow of humidified oxygen to a moist wound all day. Company officials said it's a small device that enables patients to receive constant treatment without limiting their mobility.

EO2 has "committed itself to developing the right kind of collaborative research data" that will meet the demands of an "evolving evidence-based health care system," President Joseph Moffett said in a statement.

The double-blind study is part of EO2 Concepts' ongoing research in developing its TransCu O2 technology. Double-blind studies are said to be somewhat rare in the medical device industry.

EO2 officials suggested that there is plenty of demand for its technology as more than 10 million Americans suffer from nonhealing wounds such as pressure ulcers, skin grafts and burns, according to the Agency for Healthcare Research and Quality. Roughly 1 million new cases of diabetic foot ulcers and venous leg ulcers are diagnosed each year.

Oxygen plays a pivotal role in wound healing. EO2 has collected years of data that it said shows that continuous diffusion oxygen therapy can close wounds in less than two months that have been open an average of 359 days.

 

 

 

Stay informed. Subscribe to BioMed SA news alerts.